VL002

VL002 is a preclinical-stage drug candidate being developed by PulmoSIM Therapeutics for the treatment of substance use disorder (SUD) and addiction. The asset was identified using PulmoSIM's proprietary Systemic Integration Model (SIM) platform, which integrates multi-omics data and computational modeling to repurpose existing FDA-approved drugs for new therapeutic indications. By leveraging the established safety profiles of existing medications, PulmoSIM aims to accelerate the development timeline for high-need areas like addiction. VL002 represents a "virtual lead" identified through this process, and while its specific chemical identity and biological targets remain proprietary and have not been publicly disclosed, it is currently undergoing preclinical evaluation.